Short answer
ANGIODYNAMICS INC (ANGO) filed an 8-K current report with the SEC on July 14, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.2). Item 2.02 contains only a regulatory incorporation disclaimer.
ANGIODYNAMICS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Item 2.02 contains only a regulatory incorporation disclaimer
- No earnings figures, reporting-period results, or operational metrics provided
- Investor assessment requires the referenced earnings release or exhibit
Item 7.01 · Regulation FD Disclosure
- Forward-looking statements cover future financial performance, strategy, products, costs, capital expenditures, and growth opportunities
- No operating results, guidance figures, or new business developments disclosed in the provided text
- Key investor risks include FDA actions, clinical-trial results, reimbursement changes, competition, litigation, recalls, and supply-chain pressures
- Investors should rely on AngioDynamics’ Form 10-K for the year ended May 31, 2025 for detailed risk factors
Item EX-99.1 · Exhibit EX-99.2
- FY2026 revenue $320.2M, up 9.4%, led by Med Tech growth of 18.4% to $150.0M
- Adjusted EBITDA $13.2M versus $7.6M, signaling improved operating leverage despite GAAP loss of $36.7M
- NanoKnife sales rose 64.5% quarterly, supported by Medicare coverage effective July 5, 2026
- Debt-free balance sheet with $53.9M cash and $3.1M full-year operating cash flow
- FY2027 guidance: revenue $336.0M–$341.0M, Med Tech growth 12%–15%, adjusted EBITDA $13.0M–$16.0M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ANGIODYNAMICS INC 8-K filings
Get the next ANGO 8-K as it lands
Follow ANGO for push alerts, or ask the research agent what this filing means.